

4DMedical signs research agreement with West Los Angeles VA

7 May 2024

Highlights

- 4DMedical signs Cooperative Research & Development Agreement (CRADA) with West Los Angeles VA Medical Center for utilisation of 4DMedical's XV Technology® in the Veteran Affairs Functional Lung Imaging Study (VAFLIS)
- XV Technology® will be used to characterise Veterans with undifferentiated dyspnoea and other respiratory symptoms to determine if changes in treatment pathways are required
- Announcement follows recent progress at the VA including language in the [recent budget](#) and [public support from the US Senate](#)
- Additional sites and increased utilisation builds momentum and support for a large-scale rollout within the VA

Melbourne, Australia, 7 May 2024: Respiratory imaging technology company 4DMedical Limited (ASX:4DX, "4DMedical", or the "Company") today announces the signing of a research agreement with West Los Angeles VA Medical Center.

Veteran Affairs Functional Lung Imaging Study (VAFLIS)

4DMedical has signed a Cooperative Research & Development Agreement (CRADA) to utilise XV Technology® across the spectrum of chronic respiratory conditions presenting with undifferentiated symptoms.

The study will enrol a cohort of 40 patients and utilise XV Technology® to correlate regional ventilation and ventilation heterogeneity with quality of life, the six-minute walk test and dyspnoea scores, to determine if changes can be identified in lung function post treatment. The data collected will be used to optimise treatment pathways, including possible rehospitalisation or further medical follow up.

4DMedical's patented XV Technology® measures the motion of the lungs, determining airway volumes and regional lung ventilation during spontaneous breathing. This data enables physicians to identify respiratory deficiencies earlier and with greater sensitivity.

On 1 March 2024, 4DMedical announced its participation in a pivotal burn pit research grant awarded to the Nashville VA Medical Center by the Military Exposures Research Program (MERP), and this CRADA further demonstrates the Company's commitment to the long-term lung health of US Veterans.

4DMedical MD/CEO and Founder Andreas Fouras said:

"4DMedical is targeting success in the VA through a two-prong approach: top down and bottom up, with the desired outcome being a multi-site pilot leading to a National roll-out. We have discussed recent progress in our top-down efforts, including language in the [recent budget](#) and [public support from the US Senate](#). Today we announce yet another bottom-up success with another VA site utilising our technology with the ultimate goal of improving Veteran health. Having VA doctors using our products in this way grows confidence in our solutions and builds momentum and support for a large-scale rollout within the VA.

Melbourne

Level 7 Melbourne Connect
700 Swanston Street
Carlton VIC 3053
Tel: +61 (3) 9545 5940

Los Angeles

21255 Burbank Boulevard
Suite 120
Woodland Hills CA 91367
Tel: +1 (818) 403-8490

4DMedical Limited
ABN: 31 161 684 831
Email: info@4DMedical.com
www.4DMedical.com



As momentum continues to grow in our commercialisation efforts in the VA, I look forward to keeping the market informed of our progress over coming weeks”.

–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Chief Financial Officer
Simon Glover
sglover@4dmedical.com

Administration

Company Secretary
Naomi Lawrie
companysecretary@4dmedical.com

Media Enquiries

Director of Market Development
and Communication
Hayley Willis
4Dmedia@4dmedical.com

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology[®], 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS[®]) – the first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS[™].

XV LVAS[®] and CT LVAS[™] reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

In December 2023, 4DMedical acquired Imbio, a leader in artificial intelligence medical imaging solutions for chronic lung and cardiothoracic diseases. Imbio's regulatory-cleared solutions transform the way patients are discovered, diagnosed, and treated, enabling physician productivity and more personalised care for patients.

To learn more, please visit www.4dmedical.com and www.imbio.com.